James M. Foran

Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML

Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton et al. · New England Journal of Medicine · 2018 · 1.4K citations · Full text

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

Margaret O’Donnell, Martin S. Tallman, Camille N. Abboud et al. · Journal of the National Comprehensive Cancer Network · 2017 · 651 citations · Full text

Hematological Malignancy, Version 3.2017, Oncology +14

European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma

James M. Foran, A. Z. S. Rohatiner, David Cunningham et al. · Journal of Clinical Oncology · 2000 · 471 citations

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

Martin S. Tallman, Eunice S. Wang, Jessica K. Altman et al. · Journal of the National Comprehensive Cancer Network · 2019 · 418 citations

Hematological Malignancy, Health Sciences, Medicine +15

The Beck Anxiety Inventory in a non-clinical sample

Mark Creamer, James M. Foran, Richard Bell · Behaviour Research and Therapy · 1995 · 391 citations

Psychological Co-morbidities, Psychopathology, Psychiatry +8